



Placing **NEW MPN THERAPIES** in Context Through Illustrated Case Discussions

IN-PERSON + VIRTUAL SATELLITE SYMPOSIUM

SUNDAY, JUNE 5, 2022

7:00 PM - 9:00 PM CDT

PROGRAM CHAIR

Ruben A. Mesa, MD, FACP

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoper.

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Expert Illustrations and Commentaries™ Live: Placing New MPN Therapies into Context Through Illustrated Case Discussions**.

Advances in the understanding of the pathogenesis of the myeloproliferative neoplasms (MPN) polycythemia vera (PV) and primary myelofibrosis (MF) have led to improved treatment interventions. Approximately 95% of patients with PV and 50% of patients with MF have mutations in Janus kinase 2 (JAK2), which is essential for the normal development of granulocytes, erythrocytes, and platelets. Other less common shared mutations include CALR (calreticulin mutation) and MPL (myeloproliferative leukemia virus oncogene). This CME-certified satellite will provide expert insights into the rationale for current and emerging therapeutics for patients with PV and MF, many of which target pathways that cooperate with JAK-STAT signaling. Expert Illustrations and Commentaries™ provides a unique platform designed to facilitate understanding and enrich discussion of complex subject matter through video animations, leading to improved comprehension of current and emerging therapeutics for patients with PV and MF, along with clinical application of those therapies to support patients through the continuum of care, maintain disease control, and optimize symptom management and quality of life.

In working with PER®, we strive to make this activity, along with all of PER®'s accredited continuing education (CE) activities, both useful and effective for health care professionals such as you who are involved with the care of patients with MPNs.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will create a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Ruben A. Mesa, MD, FACP

Executive Director
Mays Cancer Center
UT Health San Antonio MD Anderson Cancer Center
Mays Family Foundation Distinguished University Presidential Chair
Professor of Medicine
San Antonio, TX

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ
ptalamo@gotoper.com

AGENDA

7:00 PM	Welcome and Introductions	Ruben A. Mesa, MD, FACP
7:10 PM	Setting the Stage: Improved Methods to Characterize and Stratify Risk in MPNs	Jamile M. Shammo, MD, FASCP, FACP
7:20 PM	Illustrating How Improved Understanding of Pathologic Mechanisms Has Informed Rational Therapeutic Developments in the Field	Ruben A. Mesa, MD, FACP
7:45 PM	Current and Emerging Strategies in Polycythemia Vera: Matching Treatment to Patient	Naveen Pemmaraju, MD
8:00 PM	Applications of Novel Approaches to Practice: A Case-Based Discussion	All Faculty
8:40 PM	ASCO Annual Meeting Update/Preview	All Faculty
8:50 PM	Questions and Answers	All Faculty
9:00 PM	Adjourn	

Upcoming PER® Conferences			2022
●	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
●	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
●	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
●	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
●	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
●	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
●	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
●	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
●	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
●	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10
●	Virtual Conference		
●	In-Person + Virtual Conference		

Target Audience

This educational activity is directed toward physicians involved in the treatment of MPNs.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Determine factors that inform care plans for patients with MF and PV based on genetics, risk stratification, and symptom burden
- Explain the mechanistic rationale for the application of therapeutic approaches for the management of MPNs
- Describe evidence from investigations on treatment approaches for MF and PV, including how these findings can inform proactive strategies to manage treatment-related toxicities
- Devise strategies to integrate emerging evidence to manage clinical scenarios commonly encountered in the care of patients with MPNs along the disease continuum

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EDT Monday, June 6, 2022. To access these materials, please visit <https://www.gotoper.com/mpn0622iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/mpn0622iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until Monday, September 5, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from CTI BioPharma, Incyte Corporation, PharmaEssentia USA, and Protagonist Therapeutics, Inc.

Thank you for attending **Placing New MPN Therapies Into Context Through Illustrated Case Discussions!**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder	Other
Ruben A. Mesa, MD, FACP	AbbVie, Celgene, Constellation, CTI, Genotech, Incyte, Mays Cancer Center P30 Cancer Center, National Cancer Institute support grant (CA054174), Promedior, Samus Therapeutics	Constellation, La Jolla Pharmaceutical, Novartis, Sierra Oncology			
Jamile M. Shammo, MD, FASCP, FACP	AbbVie, Alexion, AstraZeneca, Bristol Myers Squibb, Incyte, CTI BioPharma, Kartos Therapeutics, Stemline Therapeutics	AbbVie, Alexion, Apellis, Bristol Myers Squibb, Incyte, CTI BioPharma, Novartis, Sanofi	Alexion, Blueprint Medicines, Bristol Myers Squibb, Incyte, Sanofi	AbbVie, Baxter DSMB chair: NS Pharma, DSMB member: Apellis	
Naveen Pemmaraju, MD	US Department of Defense	AbbVie, Aptitude Health, Astellas Pharma US, Blueprint Medicines, Bristol Myers Squibb, Celgene, Cimeio Therapeutics AG, ClearView Healthcare Partners, CTI BioPharma, DAVA Oncology, ImmunoGen, Incyte, Intellisphere, Novartis AG, Novartis Pharmaceuticals Corp, OncLive®, Patient Power, PharmaEssentia, Protagonist Therapeutics, Sanofi-Aventis, Stemline Therapeutics, TotalCME		Karger Publishers	Scientific/advisory committee member: Cancer.Net, CareDx, CTI BioPharma, EUSA Pharma, Novartis Pharmaceuticals, Pacylex Pharmaceuticals, PharmaEssentia; speaker/preceptorship: AbbVie, Aplastic Anemia & MDS International Foundation, Curio Science LLC, DAVA Oncology, Imedex, Magdalen Medical Publishing, Medscape, Neopharm, PeerView Institute for Medical Education, Physicians Education Resource® (PER®), Postgraduate Institute for Medicine, Stemline Therapeutics

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



Ruben A. Mesa, MD, FACP

Executive Director
Mays Cancer Center
UT Health San Antonio MD Anderson Cancer Center
Mays Family Foundation Distinguished University Presidential Chair
Professor of Medicine
San Antonio, TX

Ruben Mesa, MD, FACP, is director of UT Health San Antonio MD Anderson Cancer Center, 1 of 4 National Cancer Institute–designated cancer centers in Texas. For almost 30 years the cancer center has had a deep focus on providing world-class cancer care, advancing cancer research and educating the next generation of cancer care scientists and care providers.

After earning degrees in nuclear engineering and physiology with minors in radiation biophysics and bioengineering from the University of Illinois Urbana-Champaign, Mesa received his medical degree from Mayo Graduate School at Mayo Clinic College of Medicine and Science in Rochester, Minnesota. He completed his residency in internal medicine and his fellowship in hematology/medical oncology at Mayo. He is a fellow of the American College of Physicians and is certified by the American Board of Internal Medicine in hematology and medical oncology.

Faculty



Jamile M. Shammo, MD, FASCP, FACP

Professor of Medicine and Pathology
Rush University
Chicago, IL

Jamile M. Shammo, MD, FASCP, FACP, is a professor of medicine and pathology, Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, at Rush University Medical Center in Chicago, Illinois, where she spearheads the MDS/MPN/Bone Marrow Failure Program. As principal investigator of clinical trials in her area of expertise, and as chair of the protocol review and monitoring committee at Rush Cancer Institute, Shammo is heavily involved in education, research, and administrative activities in the Division of Hematology/Oncology. She is recognized nationally for her expertise in bone marrow failure syndromes/PNH, and she was chosen to serve in the role of a national coordinator for the US PNH registry.



Naveen Pemmaraju, MD

Associate Professor


Department of Leukemia

The University of Texas MD Anderson Cancer Center

Houston, TX

Naveen Pemmaraju, MD, completed internal medicine training at Johns Hopkins University in the Osler Medical Residency, then subsequently completed both hematology and oncology training at The University of Texas MD Anderson Cancer Center (MDACC). He was selected as a chief fellow in his second year of training. He obtained American Board of Internal Medicine certification in internal medicine, hematology, and oncology, and continued at MDACC as an assistant professor in the Department of Leukemia. In 2017, he was promoted to associate professor in the Department of Leukemia. He sees patients 2 full days of clinic per week, and he does 2 months of inpatient service per year. He also has fellow teaching responsibilities as a leukemia hematology/oncology course director and received the Gerald P. Bodey Award for Excellence in Education in 2020. His clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare myeloid malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasms, and acute myeloid leukemia. He has authored or coauthored more than 250 publications in the medical literature and has presented work at national and international meetings. He helped establish his group's first active BPDCN clinic, which now serves as a national referral base, and an active BPDCN research program with infrastructure and support for clinical and translational studies. He was named MDACC Department of Leukemia's inaugural director of the BPDCN program in 2020. He is a principal investigator in active clinical trials in the Department of Leukemia for a translational sample study of patients with BPDCN, and he was awarded a grant for identifying prognostic biomarkers in patients with BPDCN.

Experience
the new
gotoper.com



Streamlining
education
for the busy
clinician



ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER®
Physicians'
Education
Resource, LLC
gotoper.com

CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC

40th Annual
CFS®
Chemotherapy Foundation
SYMPOSIUM
Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022
New York Marriott Marquis • New York, NY
In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.

100 EXPERT
FACULTY
MEMBERS
 25 TUMOR
TYPES
 3 DAYS
 1 MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER®
Physicians'
Education
Resource, LLC
gotoper.com